Korean study says that HIFU “does not provide effective oncologic outcomes”

Posted on February 10, 2012 by Sitemaster

A new paper by clinical researchers in Korea has concluded that treatment with high-intensity focused ultrasound (HIFU) “does not provide effective oncologic outcomes even in low risk patients with prostate cancer as well as in the intermediate or high risk groups,” but does have a low associated incidence of treatment complications.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »

Brachytherapy: is it really “better” as a first-line treatment for low- and intermediate-risk prostate cancer?

Posted on February 2, 2012 by Sitemaster

An analysis of data on treatment of nearly 137,500 men treated for prostate cancer between 1991 and 2007 has suggested that permanent seed brachytherapy may be safer, less costly, and at least as effective as any other widely available form of first-line therapy for men with low- and intermediate-risk prostate cancer.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | 3 Comments »

Why men choose specific first-line types of management for localized prostate cancer

Posted on December 27, 2010 by Sitemaster

The need for patients diagnosed with early stage prostate cancer to be highly involved in the decision as to which form of management they wish to be given is well understood. However, there has been a relative dearth of data on why patients actually make their individual decisions.

Filed under: Diagnosis, Management, Treatment | Tagged: , , , , , , , , | 2 Comments »

Adverse effects of first-line treatments for localized prostate cancer

Posted on December 22, 2010 by Sitemaster

Prospective data from a significant Spanish study provide us with additional insights into the short- and longer-term adverse effects of common types of invasive therapy for localized prostate cancer.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »

Comparative data on first-line radiation therapy — and the lack thereof

Posted on April 17, 2010 by Sitemaster

The Agency for Healthcare Research and Quality (AHRQ) has released a draft version of a detailed techology assessment report entitled, “Comparative evaluation of radiation treatments for clinically localized prostate cancer: an update.”

Filed under: Management, Treatment | Tagged: , , , | Leave a Comment »

The role of surgery as first-line treatment for high-risk prostate cancer: Part III

Posted on December 19, 2009 by Sitemaster

Earlier this week we published reports on work from Memorial Sloan-Kettering Cancer Center and Johns Hopkins regarding the role of surgery as first-line treatment for men with high-risk prostate cancer. The topic appears to be coming into fashion.

Filed under: Management, Treatment | Tagged: , , | Leave a Comment »

Is surgery best reserved for first-line treatment of higher-risk prostate cancers?

Posted on December 16, 2009 by Sitemaster

One of the characteristics of a great clinician is the ability to continue to learn, to revise one’s opinions, and even radically change one’s mind based on experience. And in a recent presentation to the New York Section of the American Urological Association, Scardino has again demonstrated these very specific capabilities.

Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: , | 4 Comments »

Hormone therapy not helpful for low-risk patients receiving first-line radiation

Posted on November 3, 2009 by Sitemaster

A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed [...]

Filed under: Management, Treatment | Tagged: , , , , | Leave a Comment »

5-year biochemical recurrence rates after first-line cryotherapy

Posted on August 22, 2009 by Sitemaster

A recent publication has correlated nadir post-cryoablation PSA levels (i.e., the lowest PSA level achieved by the patient after treatment) with long-term biochemical disease-free survival in a risk-stratified cohort of patients with prostate cancer treated with cryoablation.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a Comment »

First-line therapy for localized prostate cancer: outcomes and HRQOL

Posted on June 10, 2009 by Sitemaster

The decisions patients and their doctors make about which treatment to select as first-line therapy for localized prostate cancer are commonly based on perceptions and expectations about the side effects of these treatments, as well as on the curative potential of the therapy.

Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: , , , , , | Leave a Comment »

An upper age limit for first-line treatment of localized disease?

Posted on March 2, 2009 by Sitemaster

For many years there has been intense discussion regarding who needs early detection and early (first-line) treatment for localized prostate cancer. We know that many men have indolent disease (but we don’t know who or how many). We know that most men who are diagnosed with early stage, localized disease of low or intermediate risk [...]

Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 3 Comments »

Follow

Get every new post delivered to your Inbox.

Join 269 other followers